KPMG’s Chief Medical Advisor comments on the news that investors have backed MyTomorrows, an unapproved drugs database for terminally ill.
KPMG’s Chief Medical Advisor, Professor Hilary Thomas, comments on the news that investors have backed MyTomorrows, an unapproved drugs database for terminally ill.
Hilary says: “This is a really innovative idea that will foster access to drugs for areas of unmet clinical need, where the conventional pharmaceutical model does not always support enough new medicines becoming available in a timely fashion.
“This idea and sort of access is becoming more common thanks to organisations beyond conventional pharmaceutical companies. In my opinion it is a really progressive movement that could be a life-saver for patients. The database will grant them access to drugs available in countries outside the UK, as well as the option to trial new drugs with the full support of their treating clinician.”
Hilary Thomas is an oncologist by background.
For more information, please contact:
Helen Jackson, corporate communications assistant manager
T: +44 (0)118 373 1479
M: +44 (0)790 111 5649
Follow us on twitter: @kpmguk
KPMG LLP, a UK limited liability partnership, operates from 22 offices across the UK with approximately 13,500 partners and staff. The UK firm recorded a revenue of £2.07 billion in the year ended 30 September 2016. KPMG is a global network of professional firms providing Audit, Tax, and Advisory services. It operates in 152 countries and has 189,000 professionals working in member firms around the world. The independent member firms of the KPMG network are affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. Each KPMG firm is a legally distinct and separate entity and describes itself as such.